To further confirm that ourex vivo screening platform was able to give robust and accurate readouts of TMZ sensitivity, we tested its ability to predict MGMT promoter methylation status; a well-established clinical feature of around 40-50% of all glioblastomas that epigenetically silences the expression of the key O6-methylguanine detoxifying enzyme MGMT.44 Here, MGMT is linked to glioblastoma.